Amgen's third-quarter 2021 earnings call presented several key points that could influence the stock's short-term performance:

### Positive Factors
- **Strong Revenue and Volume Growth**: Total revenues increased 4% year-over-year, driven by an 8% increase in volume growth, particularly from products like Prolia, EVENITY, and Repatha[3）。
- **Pipeline Advancements**: The company highlighted significant progress in its pipeline, including the successful launch of LUMAKRAS, ongoing clinical trials for several promising oncology assets, and the upcoming launch of Tezepelumab for severe asthma[3].
- **Financial Performance**: Non-GAAP EPS grew 11%, and the company maintained a strong financial position with $12.9 billion in cash and investments[3].

### Neutral to Negative Factors
- **Pricing Pressure**: There was notable pricing pressure, especially on Repatha due to Medicare Part D dynamics and on Aimovig due to competition from oral CGRPs[3].
- **COVID-19 Impact**: The pandemic's lingering effects on patient visits and diagnoses slightly tempered the revenue growth expectations for the year[3].
- **Guidance Adjustment**: While revenue guidance was adjusted slightly downward, the non-GAAP EPS guidance was increased, reflecting some balance in the outlook[3].

### Management's Tone and Guidance
- **Optimistic Long-Term Outlook**: Management expressed confidence in the company's ability to deliver long-term growth through its robust pipeline, strategic business development, and cost management[3].
- **Pipeline and Market Expansion**: The emphasis on expanding product indications, such as Otezla and Tezepelumab, and the strong launch of LUMAKRAS, indicate a positive long-term strategy[3].

Given these points, the short-term impact on Amgen's stock is likely to be neutral to slightly positive. The strong revenue and volume growth, along with the promising pipeline advancements, will likely offset the short-term challenges from pricing pressure and the ongoing impact of COVID-19.

**Rating: 1**